Skip to content
Screener

Avalo Therapeutics AVTX Q2 2026 earnings

Reported August 6, 2026 · Before market open

EPS-$0.83Miss by $0.25
EPS estimate-$0.58

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$0.56

Financials

Q2 2026

Income statement

See full
Operating income-$31.5M-63.2%
Net income-$36.4M-75.1%
EPS (diluted)-$0.83+56.8%

Balance sheet

See full
Cash & equivalents$85.6M+101%
Total debt$242.0K-64.4%
Total equity$448.7M+329%
Total assets$490.8M+288%

Cash flow

See full
Operating cash flow-$20.0M-75.5%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$1.1B+768%
Enterprise value$1.02B+1,095%

Returns & leverage

See full
Return on equity-36.3%—
Debt / equity0×0.0×
Current ratio19.3×+6.9×

FAQ

When did Avalo Therapeutics report Q2 2026 earnings?
Avalo Therapeutics (AVTX) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Avalo Therapeutics's Q2 2026 revenue and EPS?
Avalo Therapeutics reported eps of $-0.83 for Q2 2026.
Did Avalo Therapeutics beat estimates in Q2 2026?
EPS missed the consensus estimate of $-0.58 by $0.25.
How did Avalo Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 56.8% from $-1.92.
Where can I find Avalo Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001534120-26-000048) and the 10-Q periodic report (0001534120-26-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.